
In October 2026 the CHMP did not recommend extending Mylotarg (gemtuzumab ozogamicin) to children aged 1 to under 18 with newly diagnosed AML. Even so,[…]

The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in[…]

In October 2026 the CHMP confirmed its refusal of Yartemlea (narsoplimab) following re-examination. The case is a useful reminder of how the re-examination procedure works[…]

The CHMP has recommended Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. A tablet in this[…]

In July 2026 EMA announced a phased (rolling) review of daraxonrasib for metastatic pancreatic cancer. In October the CHMP recommended it as Rasonque. The case[…]

The CHMP meeting of 12–15 October 2026 ended with six positive opinions for new medicines, five extensions of indication and one confirmed refusal. For anyone[…]

An invented name is the first thing a prescriber, pharmacist and patient will see, and it is also a patient-safety question. For centrally authorised medicines,[…]

A marketing authorisation is not a permanent asset by default. It must be renewed once, after five years, and it can lapse in practice if[…]

For well over a decade, claims for botanical ingredients have sat in an unresolved state under the EU nutrition and health claims rules. Using them[…]

Ashwagandha remains lawful in food supplements at EU level, but national positions differ widely and the safety debate is unresolved. Companies selling it across borders[…]